FLT1 and peripheral arterial disease: In a prior experimental PAD study, where the VEGFR2-Akt-eNOS-NO system could be activated, we demonstrated that VEGF165b was upregulated and acted as an anti-angiogenic agent via VEGFR1, but not via VEGFR2 [8,15].